Cetera Advisors LLC lowered its stake in shares of Becton Dickinson and Co (NYSE:BDX) by 82.3% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,724 shares of the medical instruments supplier’s stock after selling 8,000 shares during the period. Cetera Advisors LLC’s holdings in Becton Dickinson and were worth $337,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently bought and sold shares of the company. Westwood Holdings Group Inc. increased its position in shares of Becton Dickinson and by 24.2% during the second quarter. Westwood Holdings Group Inc. now owns 1,056,487 shares of the medical instruments supplier’s stock worth $206,136,000 after purchasing an additional 205,721 shares in the last quarter. Colony Group LLC increased its position in shares of Becton Dickinson and by 2.1% during the second quarter. Colony Group LLC now owns 11,889 shares of the medical instruments supplier’s stock worth $2,320,000 after purchasing an additional 239 shares in the last quarter. State Street Corp increased its position in shares of Becton Dickinson and by 3.5% during the second quarter. State Street Corp now owns 10,270,221 shares of the medical instruments supplier’s stock worth $2,003,834,000 after purchasing an additional 342,873 shares in the last quarter. Peapack Gladstone Financial Corp increased its position in shares of Becton Dickinson and by 1.3% during the second quarter. Peapack Gladstone Financial Corp now owns 36,472 shares of the medical instruments supplier’s stock worth $7,116,000 after purchasing an additional 453 shares in the last quarter. Finally, Janney Montgomery Scott LLC increased its position in shares of Becton Dickinson and by 35.3% during the second quarter. Janney Montgomery Scott LLC now owns 43,293 shares of the medical instruments supplier’s stock worth $8,447,000 after purchasing an additional 11,300 shares in the last quarter. Institutional investors own 88.60% of the company’s stock.

Becton Dickinson and Co (NYSE:BDX) opened at $221.46 on Friday. The company has a debt-to-equity ratio of 1.44, a current ratio of 5.58 and a quick ratio of 5.03. Becton Dickinson and Co has a 12-month low of $161.50 and a 12-month high of $229.68. The stock has a market capitalization of $49,874.81, a price-to-earnings ratio of 23.05, a P/E/G ratio of 1.71 and a beta of 1.07.

Becton Dickinson and (NYSE:BDX) last released its earnings results on Thursday, November 2nd. The medical instruments supplier reported $2.40 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.37 by $0.03. Becton Dickinson and had a return on equity of 20.56% and a net margin of 8.52%. The firm had revenue of $3.17 billion for the quarter, compared to the consensus estimate of $3.14 billion. During the same period in the prior year, the firm earned $2.12 EPS. The firm’s revenue was down 2.0% on a year-over-year basis. research analysts predict that Becton Dickinson and Co will post 10.63 earnings per share for the current year.

The company also recently announced a quarterly dividend, which will be paid on Friday, December 29th. Investors of record on Friday, December 8th will be given a $0.75 dividend. This represents a $3.00 annualized dividend and a dividend yield of 1.35%. This is an increase from Becton Dickinson and’s previous quarterly dividend of $0.73. The ex-dividend date is Thursday, December 7th. Becton Dickinson and’s dividend payout ratio is presently 64.52%.

A number of brokerages have recently issued reports on BDX. Argus upped their price target on Becton Dickinson and to $235.00 and gave the stock a “buy” rating in a research report on Thursday. They noted that the move was a valuation call. Zacks Investment Research raised Becton Dickinson and from a “hold” rating to a “buy” rating and set a $234.00 price target on the stock in a research report on Tuesday, October 31st. Piper Jaffray Companies reaffirmed a “buy” rating and set a $213.00 price target on shares of Becton Dickinson and in a research report on Tuesday, September 12th. Wells Fargo & Company began coverage on Becton Dickinson and in a research report on Friday, September 22nd. They set an “outperform” rating and a $225.00 price target on the stock. Finally, Morgan Stanley upped their price target on Becton Dickinson and from $205.00 to $245.00 and gave the stock an “equal weight” rating in a research report on Friday, November 3rd. Four analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $218.36.

WARNING: This story was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this story on another publication, it was copied illegally and reposted in violation of international copyright laws. The legal version of this story can be viewed at https://www.thecerbatgem.com/2017/12/16/cetera-advisors-llc-has-337000-holdings-in-becton-dickinson-and-co-bdx.html.

About Becton Dickinson and

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Stock Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related stocks with our FREE daily email newsletter.